Abbott Laboratories (ABT) EBITDA (2009 - 2026)

Abbott Laboratories has disclosed EBITDA across 18 years of filings, most recently posting $1.3 billion for Q1 2026.

• EBITDA for Q1 2026 came in at $1.3 billion, down 20.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.7 billion (up 8.03% YoY), and the FY2025 annual result was $8.1 billion, up 17.99% from the prior year.
• EBITDA came in at $1.3 billion for Q1 2026 at Abbott Laboratories, down from $2.3 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $2.9 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
• The 5-year median for EBITDA is $1.8 billion (2022), against an average of $1.8 billion.
• Across the five-year window, EBITDA surged 70.69% in 2022 and plunged 48.18% in 2023, its largest moves.
• Abbott Laboratories' EBITDA stood at $1.3 billion in 2022, then jumped by 36.5% to $1.8 billion in 2023, then gained by 7.36% to $1.9 billion in 2024, then climbed by 17.79% to $2.3 billion in 2025, then plunged by 40.25% to $1.3 billion in 2026.
• The last three EBITDA figures came in at $1.3 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.